Tech Company Financing Transactions
Zafgen Funding Round
Alta Partners, Brookside Capital and RA Capital participated in a $45 million Series E funding round for Zafgen. The funding round was announced on 12/4/2013.
Transaction Overview
Company Name
Announced On
12/4/2013
Transaction Type
Venture Equity
Amount
$45,000,000
Round
Series E
Investors
Proceeds Purpose
Proceeds from the financing will be used to support the continued development of beloranib, the Company's obesity therapeutic. Zafgen recently reported Phase 2 study results, which demonstrated that beloranib treatment led to significant weight loss and improvements in multiple cardiometabolic risk factors in 147 obese subjects.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
175 Portland St. 4th Floor
Boston, MA 02114
USA
Boston, MA 02114
USA
Phone
Website
Email Address
Overview
Zafgen (NASDAQ: ZFGN) is developing beloranib, a novel obesity therapy that demonstrates a unique mechanism of action, re-establishing balance to the ways the body produces and uses fat stored in adipose tissue.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 12/4/2013: Exploros venture capital transaction
Next: 12/4/2013: GiveCorps venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. All VC database entries on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs